Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved four drugs for AML in 2017 (Pfizer’s Mylotarg, Novartis’s Rydapt, Agios’s Idhifa, and Jazz’s Vyxeos) and four more drugs in 2018 (Agios’s Tibsovo, AbbVie / Roche’s Venclexta, Pfizer’s Daurismo, and Astellas’s Xospata). The most recent addition to the treatment armamentarium is Bristol Myers Squibb / Celgene’s Onureg, approved as a maintenance therapy. In light of the impressive data from many newly approved drugs for AML subpopulations, the treatment paradigm is changing rapidly as it moves toward targeted and personalized therapies.
- Following the FDA’s approval of nine drugs for AML since 2017, how do physicians incorporate these additional therapies into their practice?
- What is the uptake of AbbVie / Roche’s Venclexta in patients ineligible for intensive induction? Which Venclexta-based combinations are prescribed most frequently?
- Is Astellas’s Xospata prescribed for FLT3 mutation-positive patients in the relapsed/refractory setting? How is the drug’s uptake affected by other FLT3 inhibitors, including Novartis’s Rydapt in the previously untreated setting and Nexavar in the relapsed/refractory setting?
- What will be the uptake of IDH inhibitors in patients with IDH mutations?
- What are the key prescribing drivers and obstacles facing novel therapies such as Daurismo and Onureg?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 101 U.S. hematologist-oncologists
Key drugs covered: Venclexta, Xospata, Idhifa, Tibsovo, Vyxeos, Daurismo, Mylotarg, Rydapt, Onureg
Key insights provided
- Factors influencing disease management and treatment decisions.
- Drivers and constraints of treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Acute Myeloid Leukemia - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights Acute Myeloid Leukemia US May 2021
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.